Brain Atrophy in Natalizumab ‐treated Patients with Multiple Sclerosis: A 5‐year Retrospective Study
CONCLUSIONOur results contribute to the increasing knowledge of PBVCs in natalizumab ‐treated MS patients. Our data suggests that after a significant PBVC decrease in the first year, brain atrophy rates show a slowdown during long‐term follow‐up.
Source: Journal of Neuroimaging - Category: Radiology Authors: Philipp Eisele,
Kristina Szabo,
Anne Ebert,
Michael Platten,
Achim Gass Tags: Short Communication Source Type: research
More News: Brain | MRI Scan | Multiple Sclerosis | Neurology | Radiology | Statistics | Study | Tysabri | Women